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and A. Boswood
Background: Several risk factors already have been determined for dogs with degenerative mitral valve disease (DMVD).
Risk factors often have been considered in isolation and have not always taken into account additional information provided
by the history and physical examination (PE).
Hypothesis/Objectives: Data obtained from history and PE of dogs with DMVD provide prognostic information and can
be used for risk stratification.
Animals: Client-owned dogs (n = 244) with DMVD recruited from first opinion practice.
Methods: Prospective longitudinal follow-up of dogs with DMVD. History and PE data were obtained at 6-month inter-
vals and analyzed with time-dependent Cox models to derive relative risk of cardiac death. Independent hazard ratios were
used to derive a clinical severity score (CSS), the prognostic value of which was evaluated by analyzing the median survival
times for different risk groups and ROC analysis. Analysis of the progression of CSS over time also was undertaken.
Results: History of cough, exercise intolerance, decreased appetite, breathlessness (difficulty breathing) and syncope with
PE findings of heart murmur intensity louder than III/VI and absence of respiratory sinus arrhythmia were independently
associated with outcome and allowed development of the CSS. Clinical severity score distinguished groups of dogs with sig-
nificantly different outcomes.
Conclusions and Clinical Importance: Routinely obtained clinical findings allow risk stratification of dogs with DMVD.
Results of ancillary diagnostic tests may be complementary to history and PE findings and always should be interpreted in
conjunction with these findings.
Key words: Clinical diagnosis; History; Natriuretic peptide; Physical examination; Survival analysis.
Degenerative mitral valve disease (DMVD) is a com-mon condition, accounting for approximately 75%
of cases of cardiac disease in dogs.1–3 The majority of
DMVD cases are diagnosed and treated in first opinion
practice. Clinicians detect evidence of DMVD from
early stages because of the consistent presence of a
characteristic heart murmur readily identified on physi-
cal examination (PE). Therefore, the challenge in man-
aging patients with DMVD generally is not in diagnosis
but rather in how to determine which patients have
more advanced disease and therefore are at risk of
dying of their heart disease.
Previous studies have identified prognostic risk fac-
tors.3–11 These studies consistently have demonstrated
that increased N-terminal pro B-type natriuretic peptide
(NT-proBNP) concentrations and enlarged heart size
indicate dogs at higher risk of developing congestive
heart failure (CHF) and cardiac death. These studies
simultaneously evaluated the predictive ability of numer-
ous indices obtained from history, PE and ancillary diag-
nostic tests, ignoring the fact that these data usually are
acquired sequentially. Therefore, results of these studies
can only be applied prospectively to patients once all of
the results are obtained, necessitating that all of the pre-
dictive tests are performed in all patients. A problem
encountered by first opinion practitioners is that some of
these indices, particularly those derived from echocardi-
ography, can only be obtained by undertaking diagnos-
tic tests that require substantial expertise to perform
proficiently, represent considerable cost to the client and
necessitate access to expensive diagnostic equipment or
referral of the dog to a specialist.
Clinical investigations usually occur in a standard
sequence: history taking is followed by PE after which
ancillary diagnostic tests are chosen. The results of the
history taking and PE therefore are known by the clini-
cian before deciding to undertake any additional diagnos-
tic tests. Moreover, the interpretation of the test results is
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CHF congestive heart failure
CKCS Cavalier King Charles spaniel
CSS clinical severity score
DMVD degenerative mitral valve disease
HR hazard ratio
IQR interquartile range
MST median survival time
NT-proBNP N-terminal pro B-type natriuretic peptide
PE physical examination
ROC receiving operator characteristics
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made in light of prior knowledge of the nature and sever-
ity of the patient’s disease. This prior knowledge informs
the clinician’s sense of the “pre-test probability” of a
patient having clinically relevant disease and, after evalu-
ating the results of any tests performed, the clinician can
develop a sense of the “post-test probability”.12
The aim of this study was to examine the ability of
information obtained as a part of routine history taking
and PE to predict cardiac mortality in a population of
dogs with DMVD. Furthermore, we aimed to use those
clinical and historical factors shown to be independently
predictive of a worse outcome to create a clinical sever-
ity score (CSS). The CSS could be used to categorize
dogs before interpreting results of ancillary diagnostic
tests. Our hypothesis was that the CSS would indepen-
dently predict outcome.
Materials and Methods
This prospective longitudinal study had permission from the
Royal Veterinary College Welfare and Ethics committee and
informed consent was obtained from all of the owners before en-
rolment in the study. The veterinarians from 2 first-opinion prac-
tices in London referred client-owned dogs to a research clinic for
evaluation and collection of data. The first-opinion clinicians
remained in charge of the management of the cases at all times.
Data were collected from December 2004 to the 15th of January
2014. Inclusion criteria were the presence of a left apical systolic
murmur suggestive of DMVD with echocardiographic confirma-
tion of mitral regurgitation caused by degenerative valvular
changes (eg, valvular thickening, prolapse or both). Exclusion cri-
teria were the presence of other cardiac or noncardiac illnesses at
presentation. Animals that developed comorbidities during the
study period were not excluded.
Owners were invited to participate in the study after detection
of the cardiac murmur and dogs were followed-up approximately
every 6 months until they died, were euthanized or were with-
drawn from the study. History, PE and ancillary diagnostic tests
always were obtained in the same order and according to the same
protocol as described previously.10,13,14 Thoracic radiographs were
not obtained as part of the study but were recommended to the
primary clinician when deemed necessary; the presence of CHF
was suspected on the basis of the combination of clinical signs,
echocardiographic measurements, increased NT-proBNP concen-
trations and response to treatment.
Owners were questioned about the presence of cough, exercise
intolerance, breathlessness (difficulty breathing), changes in appe-
tite and body weight over the previous 6 months and whether or
not the dog had experienced syncope. All answers were recorded
as yes/no but the owners’ comments and descriptions also were
noted. Physical examination included body condition score, mur-
mur description, heart rate and rhythm (as regular or subjectively
consistent with respiratory sinus arrhythmia), respiratory rate,
presence of dyspnea or cough on examination, presence of ascites,
and other comments about cardiovascular signs and signs from
other systems. All data were collected by the same investigator
(AB) and archived in paper files and then transferred by a quali-
fied veterinary nurse to a customized electronic database.a
Statistical Analysis
Statistical analyses were performed using commercially available
softwareb,c and freeware.d For the construction of the different
models, the assumptions were verified as required. The level of sig-
nificance was set at 5% for all analyses.
The cause of death was divided into cardiac-related and noncar-
diac causes, and the latter right-censored (as nonevents) at the
time of death to account for cardiac mortality only. Patients were
considered to have experienced cardiac-related death when no
other cause of death was known or suspected and death occurred
after a variable period of progressive cardiac remodeling in con-
junction with increased NT-proBNP concentration. Clinical evi-
dence of CHF including the presence of body cavity effusions
(ascites, pleural effusion or pericardial effusion), lung crackles on
auscultation or radiographic evidence of CHF was considered to
support the assumption that death was cardiac-related. Response
to appropriate treatment for CHF also was considered supportive
evidence of a cardiac cause for the patient’s death. Sudden death
was defined as any unexpected natural death, and was classified as
cardiac-related death unless another reason was known. Dogs also
were right-censored if they were lost to follow-up or alive at the
end of the study. Dogs were considered lost to follow-up if they
had not been presented at the research clinic or the first-opinion
practice for >9 months, and the last date of presentation was
assigned as their right-censoring date.
For ease of clinical use, the continuous variables age, body
weight and heart rate at presentation were dichotomized: the cut-
off value was determined from receiver operating characteristics
(ROC) curves as the point that provided the highest mean of sensi-
tivity and specificity to identify cardiac mortality. Body condition
score was categorized as suboptimal (<3/5) or adequate (≥3/5).
The breed of the dogs also was categorized as Cavalier King
Charles spaniel (CKCS): yes or no.
Effects of Historical and PE Data on Time to Cardiac Death. A
time-dependent Cox model was used to assess the association
between risk of cardiac death and the explanatory variables. Sur-
vival interval was defined as the time between consultations or
between last consultation and right-censoring date or date of death
caused by DMVD. The risk of each time interval was calculated
using the command: “coxph (surv (start, end, status))” from the
freeware survival analysis package, where start, end and status
referred to the starting and ending time of each time interval and
status was coded as either event (cardiac-related death) or cen-
sored. Variables with P < .10 in the univariable analysis were
included in a manual backward stepwise manner to build the mul-
tivariable regression model for survival (named herein as risk score
multivariable model). Two-way interactions were assessed for all
of the significant covariates present in the final risk score multivar-
iable model by checking the effect these interactions had 1 by 1 on
the final model. Risk was quantified as hazard ratio (HR) with
95% confidence interval.
Derivation of Clinical Severity Score. The CSS for each dog on
each visit was generated using the HR derived from all factors
shown to be significant independent predictors of outcome in the
multivariable survival analysis. When a risk factor was present,
the dog was assigned the value of the HR; when a factor was not
present the dog was assigned a value of 1. The product of the
resulting scores for all independently predictive historical and clini-
cal covariates was generated and counted as the CSS for that dog
on that visit. For ease of handling and interpretation, base 2 log
transformation was applied before further analysis.
Assessment of the CSS. The number of independently predictive
clinical signs present at a dog’s first visit was used to classify all
dogs into 4 groups: very low risk (no risk factors), low risk (1–2
risk factors), intermediate risk (3–4 risk factors) and high risk (≥5
risk factors). Considering only cardiac-related mortality, median
survival times for these 4 groups were estimated using the Kap-
lan–Meier method and compared using the log rank test.
For the assessment of the prognostic capability of 1-year car-
diac mortality from first consultation, CSS at first presentation
was assessed using ROC curve analysis. The point that provided
the highest mean of sensitivity and specificity to identify cardiac
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mortality was used as cut-off and the likelihood ratios were calcu-
lated.
Progression of CSS Over Time. For the assessment of the pro-
gression of individual CSS over time, 3 groups of dogs were
assessed: those that experienced cardiac-related death, those that
died of other causes and those that remained alive, as described
previously14 and explained in Data S1.
Results
From December 2004 to January 2014, 1,217 visits of
374 dogs were recorded. From these, 63 dogs were pre-
sented only at the first evaluation and no further infor-
mation was available from them, 5 dogs were diagnosed
with causes other than DMVD for their murmurs, and
62 were age- and weight-matched dogs followed-up as
normal controls but not affected by DMVD, resulting
in a total of 130 dogs excluded from the study. The
remaining 244 dogs (138 males and 106 females) had a
mean age of 10.4  2.9 years and median body weight
of 10.0 kg (IQR, 7.6–12.9) at presentation. These
included: 97 CKCS, 51 cross breeds, 22 Jack Russell
terriers, 16 Yorkshire terriers, 9 each Chihuahuas and
Shih-Tzus, 5 Pomeranians, 4 Poodles, 3 Bichon Frises,
2 each Chinese crested, Lurchers, Malteses, Norfolk ter-
riers, Staffordshire Bullterriers, Tibetan terriers and
Whippets and 1 each of 13 other pure breeds. These
dogs were examined a median number of 4 times
(range, 1–14).
Thirty-five dogs were presented in CHF as defined
by the study criteria. At the end of the study, 66 dogs
had died of their cardiac disease, 78 dogs had died of
noncardiac causes, 81 dogs were still alive and 19
were lost to follow-up after a variable period of time.
Of the 66 dogs that died of DMVD, 33 were
euthanized because of worsening of clinical signs con-
sistent with CHF and 33 dogs died suddenly. Forty-
nine of these 66 dogs (75%) had radiographic confir-
mation of heart disease as the cause of their clinical
signs, 12 presented with cavity effusions attributed to
advanced DMVD, 4 died suddenly due to acute
decompensation of their CHF signs and 1 was eutha-
nized because of progressive deterioration of its qual-
ity of life over a period of several months during
which it was refractory to diuresis; all of the 66 dogs
had cardiac enlargement and progressive increases in
NT-proBNP with increased concentration on the last
consultation before death. The estimated MST for car-
diac mortality of the 244 dogs was 1,977 days (95%
CI, 1,751–2,203 days).
Results of the univariable analysis of individual fac-
tors recorded from history and PE are shown in
Table 1. The risk score multivariable model then was
constructed with the variables: CKCS (yes/no), history
of cough, of exercise intolerance, of decreased appetite,
of breathlessness (difficulty breathing) and of syncope;
and PE assessment of body condition score, murmur
grade, heart rate, heart rhythm (sinus arrhythmia/sinus
rhythm) and presence of dyspnea. No interaction was
detected between any pair of variables remaining in the
final multivariable model. The resulting multivariable
model is presented in Table 2.
According to the risk score multivariable model HRs,
the CSS was calculated for each dog at every consulta-
tion. Dogs with no negative prognostic factors from the
risk score multivariable model had a log2 (CSS)
score = 0; dogs with 1 factor had a score between 0.9 and
1.9; 2 factors = 2.1–3.6; 3 factors = 3.4–4.9; 4 factors =
5.0–6.1; 5 factors = 6.4–7.3; and 6 factors = 8.2–8.3.
Table 1. Univariable time-dependent Cox regression analysis of factors associated with cardiac mortality derived
from the history and physical examination.
nDogs (nVisits) HR (95% CI) P-Value
Signalment
Age (>13.3 years old/≤13.3 years olda) 68 (164)/212 (821) 0.92 (0.47–1.79) .806
Body weight (>15 kg/<15 kga) 42 (148)/209 (836) 0.60 (0.26–1.40) .240
Sex (female /malea) 106 (418)/138 (567) 0.91 (0.54–1.49) .718
CKCS (yes/noa) 97 (425)/147 (560) 2.09 (1.27–3.43) .004
History
Cough (yes/noa) 123 (306)/184 (679) 7.69 (4.32–13.73) <.001
Exercise intolerance (yes/noa) 54 (122)/232 (863) 5.12 (3.07–8.55) <.001
Appetite (decreased/normala) 49 (71)/238 (914) 3.30 (1.79–6.10) <.001
Weight loss (yes/noa) 143 (260)/219 (725) 1.30 (0.77–2.20) .320
Breathlessness (yes/noa) 141 (311)/196 (674) 4.10 (2.45–6.86) <.001
Syncope (yes/noa) 37 (58)/228 (927) 2.73 (1.39–5.34) .003
Physical examination
Body Cond. score (<3/≥3a) 111 (232)/222 (749) 1.93 (1.16–3.19) .011
Murmur grade PE (>III/≤IIIa) 156 (461)/169 (524) 7.22 (3.68–14.18) <.001
Heart rate PE (>135/≤135a) 156 (397)/178 (588) 3.64 (2.15–6.16) <.001
Rhythm PE (SR/SAa) 160 (376)/196 (609) 3.81 (2.27–6.41) <.001
Dyspnea PE (yes/noa) 31 (41)/232 (941) 15.66 (8.72–28.14) <.001
nDogs, total number of dogs with the factor at a particular visit; nVisits, total number of visits a factor was detected; HR, hazard ratio;
CI, confidence interval; CKCS, Cavalier King Charles spaniel; PE, physical examination; SR, assumed sinus rhythm; SA, assumed sinus
arrhythmia.
aShows the reference category for the dichotomous variables.
Variables with the p-value in marked bold were considered significant at the univariable level.
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None of the dogs had all 7 factors at any of the visits.
Taking only the observations from the first visit for each
dog, and grouping them as very low risk, low risk, inter-
mediate risk and high risk, there was a significant differ-
ence among groups over time in the proportion that had
not experienced cardiac mortality (P < .001; Table 3 and
Fig 1).
A total of 31 dogs died of cardiac-related causes
within the first 365 days after initial presentation (med-
ian, 171 days; IQR, 106–304 days). The area under the
ROC curve for the individual CSS at presentation to
detect 1-year cardiac mortality was 0.83 (95% CI, 0.74–
0.91), with sensitivity = 0.81 and specificity = 0.77 for
the log2 transformed CSS = 3.30. Using this cut-off
value, the positive likelihood ratio was 3.51 and the
negative likelihood ratio 0.25.
For the assessment of the progression of the CSS
over time, 125 dogs met the inclusion criteria: 33 dogs
in Group 1, 44 dogs in Group 2 and 48 dogs in Group
3 (42 alive and 6 lost to follow-up). After graphical
assessment of the progression of the log2 (CSS) over
time (Fig 2), a linear repeated measures model showed
that score was overall different among groups
(P < .001) and among visits (P < .001). Post hoc analy-
sis showed that the log2 (CSS) was higher at each visit
for group 1 compared with the other 2 groups, and that
there was no significant difference between groups 2
and 3 at any visit (Table 4).
Discussion
The findings support our original hypothesis. Several
commonly observed historical and clinical findings in
dogs with DMVD are independently predictive of a
Table 2. Multivariable time-dependent Cox regression
analysis of factors independently associated with cardiac
mortality derived from the history and physical exami-
nation.
Factors HR (95% CI) P-Value
History of Cough (yes/noa) 3.85 (2.11–7.03) <.001






History of breathlessness (yes/noa) 1.93 (1.09–3.41) .024
History of syncope (yes/noa) 2.28 (1.15–4.52) .018
Murmur grade (>III/≤IIIa) 3.08 (1.51–6.28) .002
Rhythm on PE (SR/SAa) 2.33 (1.35–4.03) .002
HR, hazard ratio; CI, confidence interval; PE, physical examina-
tion; SR, assumed sinus rhythm; SA, assumed sinus arrhythmia.
aShows the reference category for the dichotomous variables.
Table 3. Median survival time for the four severity groups according to the number of risk factors shown at presen-
tation.
Risk Factors n Median Survival Time (95% CI) IQR Statistical Comparison
Very low None 63 nd nd A
Low 1 or 2 114 1,977 (nd) nd A
Intermediate 3 or 4 57 1,013 (17–2,009) 312–1,954 B
High 5 or more 10 167 (19–314) 96–980 C
Overall 244 1,977 (1,751–2,202)
A significant difference between the groups is indicated by different letters.
CI, confidence interval; IQR, interquartile range; nd, not determined.
Fig 1. Kaplan–Meier survival curves of dogs categorized accord-
ing to the number of risk factors manifested at first presentation.
Fig 2. Graphic assessment of the progression of the mean indi-
vidual clinical severity score (CSS) (standard error of the mean)
over time in the 3 study groups. Group 1: dogs suffering cardiac
death; Group 2: dogs dying of non-cardiac causes; Group 3: dogs
alive or lost to follow-up.
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worse outcome. Affected dogs that die of their disease
show a progressively higher number of these signs as
their disease progresses, and finding several of these
signs in combination is much more strongly predictive
of a worse outcome than any individual sign in isola-
tion.
Degenerative mitral valve disease is characterized by
mitral valve insufficiency that compromises forward
stroke volume and causes left-sided volume overload
eventually resulting in the activation of compensatory
mechanisms. The presence of an apical systolic heart
murmur usually is the first detectable clinical finding in
patients with DMVD.15,16 Decreased cardiac output
may cause some of the initial clinical signs, which may
only be present during circumstances that necessitate
increased cardiac demand (ie, exercise intolerance). In
small breed dogs, DMVD progresses slowly over
months to years.1 The rate of progression is variable
among dogs and many do not die of their DMVD.11
This was apparent in our population, in which from a
total of 144 dogs that died, only 66 did so because of
their cardiac disease, representing 46% of all deaths.
Our initial observation (subsequently supported by
this study) was that small breed dogs with DMVD tend
to develop several, sometimes subtle, clinical signs
before they develop CHF as defined in our study. We
therefore aimed to analyze factors that can be obtained
in general veterinary practice before performing any
ancillary diagnostic tests and that, under normal cir-
cumstances, consciously or sub-consciously, are already
guiding and dictating the clinician’s subsequent deci-
sions regarding the patient.
Risk stratification is the statistical process that
enables detection and categorization of characteristics
associated with increased probability of experiencing an
unwanted outcome.17 Several risk factors for CHF and
cardiac death for dogs with DMVD already have been
reported in the veterinary literature, including age, sex,
breed, murmur intensity, cardiac silhouette size on tho-
racic radiographs, echocardiographically detected sever-
ity of valvular changes, degree of mitral regurgitation,
left atrial size, left ventricular size in diastole, transmi-
tral flow pattern and circulating concentrations of car-
diac biomarkers.5,7,8,10,11,13,18–27 Some studies have
shown that a higher heart rate, exercise intolerance,
increased respiratory effort, dyspnea, cough, syncope
and arrhythmias are significant predictors of worse out-
come at the univariable level but these factors do not
consistently appear in final multivariable models of dif-
ferent studies.6,11,28
Analyzing all of the data routinely collected from his-
tory and PE, we found that all of those we examined,
except for weight loss, were associated with cardiac
mortality at the univariable level (Table 1). Our multi-
variable model identified 7 independent risk factors that
allowed us to develop a clinical scoring system of the
patients’ disease severity. The CSS had an accuracy
determined by ROC analysis of 83% (95% CI, 74–
91%) for the prediction of cardiac-related death in the
following year in our population. Moreover, the likeli-
hood ratio confirms that the CSS system is helpful to
predict which dogs are more likely to die of their
DMVD, and also which are unlikely to do so. This
implies that the information collected by a clinician
before choosing to perform any ancillary diagnostic test
is already informative about the prognosis and illus-
trates the importance of performing a thorough clinical
evaluation of cases before undertaking additional tests.
The subsequent analysis of the change over time in
the CSS in dogs that ultimately die of their DMVD
indicates a gradual increase, implying an increase in the
number of clinical signs that manifest over a period of
a few years. Dogs with DMVD that die of noncardiac
diseases tend to develop fewer clinical signs. Although
some clinical signs of advanced heart disease are shared
by other potentially life-threatening conditions (eg,
cough, loss of appetite, exercise intolerance), dogs that
die of other disease develop a few, but not many, of the
clinical signs associated with progressive DMVD. Their
CSS therefore may increase before death but not to the
same extent that it does in dogs dying of their heart dis-
ease.
Using a single aspect of history or PE to guide deci-
sion making is fraught with potential problems. The
advantage of the CSS system is that it allows the inte-
gration of several aspects of the history and PE and
therefore will have increased relevance in the clinical
setting. We found that the development of cough during
the progression of DMVD was strongly and indepen-
dently associated with higher hazard of cardiac-related
Table 4. Estimated adjusted mean  SE for the individual log2 (CSS) for each group and visit.
Visit-3 Visit-2 Visit-1 Overall
Group 1 3.86  0.31 4.44  0.31 5.74  0.31 4.68  0.27
A
Group 2 2.18  0.27 2.53  0.27 3.25  0.27 2.65  0.23
B
Group 3 1.65  0.26 2.04  0.26 2.05  0.26 1.91  0.22
B






A significant difference was found between the groups with different letters.
Group 1: dogs suffering cardiac death; Group 2: dogs dying of non-cardiac causes; Group 3: dogs alive or lost to follow-up.
SE, standard error; CSS, clinical severity score.
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death, having the highest HR of any single factor in the
final multivariable model. A recent report found that
cough in dogs with DMVD is not likely to be due to
CHF.29 Most of the dogs that developed a cough dur-
ing the clinical progress of their disease in our popula-
tion did so at a much earlier stage than they developed
overt signs of CHF. Therefore, the explanation that
cough is caused by left atrial enlargement and concomi-
tant airway abnormalities rather than overt CHF
appears to be supported by these results. The develop-
ment of cough in a patient with DMVD however still
should be regarded as possible evidence of progression
of that patient’s disease.
As shown previously by our group, heart rate and
heart rate variability change gradually with progression
of disease.14 However, these factors also change in dogs
with DMVD that die of noncardiac causes. The result-
ing conclusion is that these are insensitive prognostic
markers for cardiac death because of DMVD, but pos-
sess excellent negative predictive value. This is reflected
in the multivariable model in this study showing that
dogs with a regular sinus rhythm have a higher risk of
dying of DMVD than dogs that maintain their respira-
tory sinus arrhythmia on PE.
The severity of mitral regurgitation has been shown
to be associated with the intensity of the resultant mur-
mur.19,30 In this study, we observed that a heart mur-
mur intensity higher than III/VI is associated with a
higher risk of cardiac mortality than a murmur of grade
III/VI or lower, demonstrating that the intensity of the
murmur is associated with outcome.
Certain weaknesses of this study should be acknowl-
edged. One limitation is the subjective nature of the
owners’ perceptions of a patient’s clinical signs. This
however reflects the reality of relying on observations
made by clients in practice. Another limitation is that we
did not ask owners to record resting respiratory rate at
home. Published evidence suggests that the onset of
CHF may be heralded by an increased respiratory rate.31
Dogs with subclinical heart disease have normal respira-
tory rates.32 This would therefore be a useful clinical
sign to monitor in patients but would not be information
available to a clinician on the initial presentation of a
patient with DMVD, because clients would need to be
instructed to obtain this information. Another limitation
is that the period of time between visits was not the same
for all dogs and that the exact date of appearance of
clinical signs was not known. This may have influenced
the results. The cumulative nature of the data analyzed
however makes it unlikely that once 1 of these signs
appeared the dog would not present with that sign on
subsequent visits. A last limitation is that euthanasia
represents a unique situation in veterinary medicine and
a common factor influencing any veterinary study assess-
ing survival. Euthanasia generally is requested by an
owner who fears the pet no long has an adequate quality
of life, but this does not necessarily reflect the severity of
DMVD. As with any novel clinical prediction tool, the
first development phase needs to be followed by a pro-
spective validation before it can be adopted in clinical
practice. Despite the above limitations, we consider that
this model provides a basis for a validation study in a
larger population in which the assessment of the impact
of the implementation of this risk stratification system in
practice can be evaluated.
In summary, this study shows that data obtained
from history and PE, specifically history of cough, exer-
cise intolerance, decreased appetite, breathlessness (diffi-
culty breathing) and syncope as well as murmur grades
louder than III/VI and loss of respiratory sinus arrhyth-
mia, are independent indicators of disease progression
for DMVD and are predictive of cardiac death. This
knowledge can be developed into a scoring system to
assist clinical decision making and may improve the
interpretation of subsequent diagnostic test results for
improved management of cases both in first opinion
and referral practice.
Footnotes
a FileMaker Pro 11.0v3, Santa Clara, CA
b IBM SPSS Statistics 20, Armonk, NY
c GraphPad Prism 6, San Diego, CA
d R version 3.0.2, R Core Team (2013). R: A language and envi-
ronment for statistical computing. R Foundation for Statistical
Computing, Vienna, Austria. http://www.R-project.org/
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